株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

血友病の世界市場:産業分析と将来展望

Global Hemophilia Market: Industry Analysis & Outlook 2017-2021

発行 Koncept Analytics 商品コード 246749
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.31円で換算しております。
Back to Top
血友病の世界市場:産業分析と将来展望 Global Hemophilia Market: Industry Analysis & Outlook 2017-2021
出版日: 2017年03月27日 ページ情報: 英文 86 Pages
概要

当レポートでは、世界の血友病治療薬の市場について分析し、疾患の概要や市場の基本構造、市場規模の動向見通し (患者数/金額ベース、過去・今後5年間分)、種類別 (血友病A/B)・治療クラス別・重症度別および地域別の詳細動向、主な市場促進・阻害要因、市場競争・資本取引の状況、主要企業のプロファイルなどをまとめてお届けします。

第1章 市場概要

  • 血友病
  • 血友病の種類
  • 兆候・症状
  • 診断/治療法

第2章 世界市場の分析

  • 市場規模 (金額ベース)
  • 市場規模の予測 (金額ベース)
  • 治療クラス別の市場規模 (金額ベース)
    • 従来型因子の市場規模 (予測値、金額ベース)
  • 種類別の市場規模
    • 血友病Aの市場規模 (予測値、金額ベース)
    • 血友病Aの市場規模:治療クラス別 (予測値)
    • 血友病Aの市場規模:重症度別
    • 血友病インヒビターの市場規模 (予測値、金額ベース)
    • 血友病Bの市場規模 (予測値、金額ベース)
    • 血友病Bの市場規模:治療クラス別 (予測値)
    • 血友病Bの市場規模:重症度別

第3章 地域市場の分析

  • 米国市場
    • 市場規模 (金額ベース)
    • 市場規模の予測 (金額ベース)
    • 市場規模:種類別
    • 血友病Aの市場規模予測 (金額ベース)
    • 血友病Aの患者数予測 (治療済み患者数)
    • 血友病Aの患者数予測 (小児患者数)
    • 血友病Aの患者数予測 (成人患者数)
    • 血友病Bの市場規模予測 (金額ベース)
    • 血友病Bの患者数予測 (治療済み患者)
  • 欧州市場
    • 患者数予測
    • 血友病Aの患者数予測
    • 血友病Bの患者数予測

第4章 市場のダイナミクス

  • 成長促進要因
    • 予防的治療への関心増加
    • 第VIII因子市場の成長
    • 診断率の上昇
    • 医療費の増大
  • 主要動向
    • 新型の血友病治療薬の開発
    • 皮下投与
    • 遺伝子組み換え型の第VIII・第IX因子製剤の需要増加
    • 遺伝子療法の人気
  • 課題
    • 多額の治療コスト
    • 新たな治療法への切り替えへの抵抗感

第5章 競争環境

  • 世界の血友病市場
    • 市場収益額と時価総額との比較
  • 世界の血友病A市場
    • 市場シェア
    • 第VIII因子製品の市場シェア
    • 第VIII因子遺伝子療法の市場シェア予測
  • 世界の血友病B市場
    • 市場シェア
    • 第IX因子製品の市場シェア
    • 第IX因子遺伝子療法の市場シェア予測

第6章 企業プロファイル

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes abnormal bleeding with poor clotting. It is classified into hemophilia A, hemophilia B, hemophilia C, and hemophilia with inhibitors.

Treatment for hemophilia is done via replacement therapy, prophylactic therapy, on-demand therapy, gene therapy and many others. Gene therapy is being regarded as an attractive option for treatment of hemophilia. By the year 2030, the pharmaceutical companies are expected to launch their gene therapy treatment for hemophilia, and this might affect the market dynamics at large.

The growth factors of the hemophilia market include increased focus on prophylactic treatment, growing market for FVIII, increasing diagnosis rate, and increasing healthcare expenditure. Major trends of the market include development of novel hemophilia treatment, subcutaneous dosing and growing popularity of gene therapy. Further, growth prospects are hindered by high cost of therapy and consumer's reluctance in switching to new therapy options.

The report offers an in-depth analysis of the global hemophilia market. It also covers the global as well as regional aspect of the market. The top notch players in the market exhibit a very close competition. The report profiles Pfizer Inc., Bayer Group, Shire PLC, and Novo Nordisk.

Table of Contents

1. Market Overview

  • 1.1 Hemophilia
  • 1.2 Types of Hemophilia
  • 1.3 Signs & Symptoms
  • 1.4 Diagnosis & Treatment

2. Global Market Analysis

  • 2.1 Global Hemophilia Market by Value
  • 2.2 Global Hemophilia Market Forecast by Value
  • 2.3 Global Hemophilia Market by Therapeutic Class
    • 2.3.1 Global Hemophilia Traditional Factors Market Forecast by Value
  • 2.4 Global Hemophilia Market by Type
    • 2.4.1 Global Hemophilia A Market Forecast by Value
    • 2.4.2 Global Hemophilia A Market Forecast by Therapeutic Class
    • 2.4.3 Global Hemophilia A Market by Severity
    • 2.4.4 Global Hemophilia with Inhibitors Market Forecast by Value
    • 2.4.5 Global Hemophilia B Market Forecast by Value
    • 2.4.6 Global Hemophilia B Market Forecast by Therapeutic Class
    • 2.4.7 Global Hemophilia B Market by Severity

3. Regional Market Analysis

  • 3.1 The US
    • 3.1.1 The US Hemophilia Market by Value
    • 3.1.2 The US Hemophilia Market Forecast by Value
    • 3.1.3 The US Hemophilia Market by Type
    • 3.1.4 The US Hemophilia A Market Forecast by Value
    • 3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
    • 3.1.6 The US Hemophilia A Market-Pediatric Patients Volume Forecast
    • 3.1.7 The US Hemophilia A Market- Adult Patients Volume Forecast
    • 3.1.8 The US Hemophilia B Market Forecast by Value
    • 3.1.9 The US Hemophilia B Market-Treated Patient Volume Forecast
  • 3.2 Europe
    • 3.2.1 Europe's Hemophilia Market- Patient Volume Forecast
    • 3.2.2 Europe's Hemophilia A Market- Patient Volume Forecast
    • 3.2.3 Europe's Hemophilia B Market- Patient Volume Forecast

4. Market Dynamics

  • 4.1 Growth Drivers
    • 4.1.1 Increased Focus on Prophylactic Treatment
    • 4.1.2 Growing Market for FVIII
    • 4.1.3 Increasing Diagnosis Rate
    • 4.1.4 Increasing Healthcare Expenditure
  • 4.2 Key Trends
    • 4.2.1 Development of Novel Hemophilia Treatments
    • 4.2.2 Subcutaneous Dosing
    • 4.2.3 Increasing Demand for Recombinant Versions of Factor VIII & FIX Drugs
    • 4.2.4 Popularity of Gene Therapy
  • 4.3 Challenges
    • 4.3.1 High Cost of Treatment
    • 4.3.2 Reluctance to Switch to New Therapies

5. Competitive Landscape

  • 5.1 Global Hemophilia Market
    • 5.1.1 Revenue and Market Cap Comparison
  • 5.2 Global Hemophilia A Market
    • 5.2.1 Market Share
    • 5.2.2 Factor VIII Products Market Share
    • 5.2.3 Factor VIII Gene Therapy Market Share Forecast
  • 5.3 Global Hemophilia B Market
    • 5.3.1 Market Share
    • 5.3.2 Factor IX Products Market Share Forecast
    • 5.3.3 Factor IX Gene Therapy Market Share Forecast

6. Company Profiles

  • 6.1 Pfizer Inc.
    • 6.1.1 Business Overview
    • 6.1.2 Financial Overview
    • 6.1.3 Business Strategies
  • 6.2 Bayer Group
    • 6.2.1 Business Overview
    • 6.2.2 Financial Overview
    • 6.2.3 Business Strategies
  • 6.3 Shire PLC
    • 6.3.1 Business Overview
    • 6.3.2 Financial Overview
    • 6.3.3 Business Strategies
  • 6.4 Novo Nordisk
    • 6.4.1 Business Overview
    • 6.4.2 Financial Overview
    • 6.4.3 Business Strategies

List of Charts

  • Depiction of Inheritance of Hemophilia
  • Types of Hemophilia
  • Global Hemophilia Market by Value (2012-2016)
  • Global Hemophilia Market Forecast by Value (2017-2021)
  • Global Hemophilia Market by Therapeutic Class (2016- 2030)
  • Global Hemophilia Traditional Factors Market Forecast by Value (2016-2021)
  • Global Hemophilia Market by Type (2016)
  • Global Hemophilia A Market Forecast by Value (2016-2021)
  • Global Hemophilia A Market Forecast by Therapeutic Class (2016- 2030)
  • Global Hemophilia A market by Severity (2016)
  • Global Hemophilia with Inhibitors Market Forecast by Value (2016-2021)
  • Global Hemophilia B Market Forecast by Value (2016-2021)
  • Global Hemophilia B Market Forecast by Therapeutic Class (2016- 2030)
  • Global Hemophilia B Market by Severity (2016)
  • The US Hemophilia Market by Value (2012-2016)
  • The US Hemophilia Market Forecast by Value (2017-2021)
  • The US Hemophilia Market by Type (2016)
  • The US Hemophilia A Market Forecast by Value (2016-2021)
  • The US Hemophilia A Market-Treated Patient Volume Forecast (2016-2021)
  • The US Hemophilia A Market-Pediatric Patients Volume Forecast (2016-2021)
  • The US Hemophilia A Market- Adult Patients Volume Forecast (2016-2021)
  • The US Hemophilia B Market Forecast by Value (2016-2021)
  • The US Hemophilia B Market-Treated Patient Volume Forecast (2016-2021)
  • Europe's Hemophilia Market- Patient Volume Forecast (2016-2021)
  • Europe's Hemophilia A Market- Patient Volume Forecast (2016-2021)
  • Europe's Hemophilia B Market- Patient Volume Forecast (2016-2021)
  • Market Share of Hemophilia A Patients on Prophylaxis in the US (2014-2016)
  • Market Share of Hemophilia B Patients on Prophylaxis in the US (2014-2016)
  • Global Hemophilia A Factor VIII Products Market by Value (2016-2021)
  • Global Identified Hemophilia Patients Volume (2005-2016)
  • Global Healthcare Expenditure (2012-2016)
  • Global Hemophilia A Market Share by Company (2016)
  • Global Hemophilia A Factor VIII Products Market Share by Company (2021/2030)
  • Global Hemophilia A FVIII Gene Therapy Market Share Forecast (2030)
  • Global Hemophilia B Market Share by Company (2016)
  • Global Hemophilia B Factor IX Products Market Share Forecast (2021/2030)
  • Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
  • Pfizer Inc.'s Revenue Share by Major Business Segment (2016)
  • Pfizer Inc.'s Revenue and Net Income (2012-2016)
  • Pfizer Inc. R&D Expenses (2015-2016)
  • Bayer Group's Net Sales Share by Business Segments (2016)
  • Bayer Group's Net Sales and Net Income (2012-2016)
  • Shire PLC's Revenue Share by Franchise (2016)
  • Shire PLC's Revenue and Net Income (2012-2016)
  • Novo Nordisk's Net Sales Share by Business Segments (2016)
  • Novo Nordisk's Net Sales and Net Profit (2012-2016)

List of Tables

  • Signs & Symptoms of Hemophilia
  • Development of New Novel Hemophilia Treatments (2016)
  • Developed and Upcoming Long Acting Factor VIII Drugs
  • Factor IX Products in Development
  • Upcoming Hemophilia Gene Therapy Candidates (2016-2030)
  • Global Hemophilia Revenue & Market Cap Comparison by Key Players (2016)
  • Major Business Segments of Pfizer Inc.
  • Major Products Developed by Pfizer Inc. (Since November 1, 2016)
  • Bayer Group's R&D Expenses by Business Segments (2016)
  • Shire PLC's Major Product Approvals & Launches (2016)
  • Shire PLC's Major Product Pipeline (2016)
  • Novo Nordisk's Research and Development (2014-2016)
  • Novo Nordisk's Product Pipeline (2016)
Back to Top